JAK2 and myeloproliferative neoplasm: Epistatic interactions between mutations influenced the availability of adaptive trajectories in microbial evolution experiments [103] and the order in which Janus kinase 2 (JAK2) and tet methylcytosine dioxygenase 2 (TET2) driver mutations were acquired in myeloproliferative neoplasms altered their biology, clinical features, and future evolutionary paths [104].